RISK FACTORS OF DAMAGE OF THE CARDIOVASCULAR SYSTEM IN PATIENTS WITH PRIMARY OSTEOARTHRITIS WITH IDENTIFIED CORONARY ATHEROSCLEROSIS

The aim of the research is to assess risk factors of damage of the cardiovascular system in patients with primary osteoarthritis with identified coronary atherosclerosis.

Materials and methods. 52 patients at the mean age 41 [34; 52] were involved in the study. Therewere 37 womenand 15 menamongthem. Planned contrast study of the coronary arteries (on the apparatus ALLURAXperFD20 Philips) were performed to all patients. As a result, hemodynamically insignificant (less than 50%) atherosclerotic stenosis of the heart vessels was verified in this group. In all patients were determined such indicators as: height, weight, waist circumference with the calculation of body mass index by Kettle`s method. The questionnaire was used to assess the presence of risk factors for development of cardiovascular diseases, such as: smoking, family history of cardiovascular diseases, hypodynamia. In addition, all patients had daily monitoring of arterial pressure by the device «Kardiotechnika– 07-AP-3», clinical and biochemical blood tests and the total cardiovascular risk was calculated.

Results. Each patient had from 1 to 6 risk factors of cardiovascular diseases, the median was [25-th; 75-th percentiles] 3 [2; 5]. In the group of women family history of cardiovascular diseases, hypodynamia and hypertension met more often the in the group of men (р=0,002). Men with higher frequency demonstrated the presence of bad habits (smoking), high levels of triglycerides and low-density lipoproteins (p=0.0001). The correlation analysis revealed that the incidence of hypertension, hypodynamia and dyslipidemia was associated with the duration of osteoarthritis, the intensity of pain according to visual analog scale and the number of affected joints.

Conclusion. The presense of generalized subclinical inflammation in patients with ostheoarthritis together with the classic risk factors of development of cardiovascular diseases, probably mediates the early beginning of atherosclerosis in this category of patients.

1. Alekseeva L.I. Osteoarthrosis risk factors. S cientific and practical rheumatology. 2000; 2: 37. [in Russian].

2. Badokin V.V. The signification of inflammation in development and progress of ostheoarthritis. Consilium medicum. 2009; 11(9): 91-95. [in Russian].

3. Badokin V.V. Nonsteroidal anti-inflammatory drugs in practice of physihian of out-patien t department: clinical pharmacotherapy of ketoprofen. Consiliummedicum. 2007; 5(4): 108-113. [in Russian].

4. Voronkova N.B., Khrustalev O.A. Influence of arterial hypertension and obesity on current and clinic of ostheoarthritis of knee`s joints. Internet resource: http://www.cardiosite.ru (date of the application 04.09.2018) [in Russian].

5. Karpov Yu.A., Kulikova T.Yu. Nonsteroidal anti-inflammatory drugs: issues of cardiovascular safety. Topical issues of diseases of the heart and blood vessels. 2010; 4: 60-65. [in Russian].

6. Mendel’ O.I., Naumov A.V., Alekseeva L.I. Osteoarthrosis and cardiovascular diseases. Overall risk factors and clinical and pathogenetic relationships. Therapy optimization. Preventive medicine. 2010; 3: 35-41. [in Russian].

7. Nasonov E.L., Popkova Т.V. Anti-inflammatory therapy of atherosclerosis — the contribution and lessons of rheumatology. Scientific and practical rheumatology. 2017; 55 (5): 465-473. [in Russian].

8. Naumov A.V., Shamuilova M.M., Kocelapova Je.Ju. Osteoarthrosis in modern clinical practice: analysis of factors and recommendations. Therapist. 2009; 11: 4-15. [in Russian].

9. Popkova T.V., Novikova D.S., Nasonov E.L. Cardiovascular diseases in rheumatoid arthritis: new data. Scientific and practical rheumatology. 2016; 54 (2): 122-128. [in Russian].

10. Russian clinical guidelines. Rheumatology (edited by Nasonov E.L.). M.: GEOTAR — Media. 2017; 464 р. [in Russian].

11. Starodubtseva I.A. Effect of complex therapy on markers of inflammation in patients with secondary osteoarthritis. The Russian Archives of Internal Medicine. 2015; (6): 42-49. [in Russian].

12. Udachkina E.V., Novikova D.S., Popkova Т.V. et al. The role of interleukin 6 in the development of atherosclerosis in rheumatoid arthritis. Modern rheumatology. 2013; 7 (3): 25-32. https: //doi. org/10.14412/1996-7012-2013-7. [in Russian].

13. Tsvinger S.M., Govorin A.V., Portyannikova O.O. Pathogenic connections between osteoarthrosis and atherosclerosis. EHNI Transbaikalian medical messenger. 2017; (4): 164-173. http://zabmedvestnik.ru. [in Russian].

14. Chichasova N.V. Problem of pain in osteoarthrosis. The attending physician. 2007; 2: 45-49. [in Russian].

15. Ambramson S.B. Osteoarthritis and nitric oxide. Osteoarthritis and Cartilage. 2008; 16 Suppl 2: S15-20. doi: 10.1016/S10634584(08)60008-4.

16. Benito M.J., Veale D.J., FitzGerald О. Synovial tissue inflammation in early and late osteoarthritis. Ann. Rheum. Dis. 2005; 64: 1263-1267.

17. Bijlsma J.W., Berenbaum F., P.Lafeber F. Osteoarthritis: an update with relevance for clinical practice. Lancet. 2011; 377: 2115–2126.

18. Conaghan P.G., Vanharanta H., Dieppe P.A. Is progressive osteoarthritis an atheromatous vascular disease? Ann.Rheum. Dis. 2005; 64: 1539–1541.

19. Fan Z., Ban B., Yang H. Freshly isolated osteoarthritic chondrocytes are catobolically more active than normal chondrocytes, but lessresponsive to catabolic stimulation with IL-1β. Arthr. Rheum. 2005; 52: 1.

20. Kean W.F., Kean R., Buchanan W.W. Osteoarthritis: symptoms. Signs and source of rain. Inflammopharmacology. 2004; 1: 3-31.

21. Kerin A., Patwari P., Kuettner K. Molecular basis of osteoarthritis: biomechanical aspects. Cell Mol Life Sci. 2002; 59: 27—35.

22. Kidd B.L., Urban L.A. Mechanisms of inflammatory pain. Br. J.Anaesth. 2001; 87: 3-11.

23. Lawrence R.C., Felson D.T., Helmick C.G. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2007; 58: 26-35.

24. Mitchell P.G., Magna H.A., Reeves L.M. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. Clin Invest. 1996; 97: 761–768.

25. Schaeverbeke T., Heloire F., Deray G. How to watch over a patient treated with NSAID in relation to the cardiovascular and renal risk. Press Med. 2006; 35(99): 41-46.